Adverum faces murky future after review turns up deeper safety issues for gene therapy
Three months after revealing that a patient lost significant vision in one eye after receiving its experimental gene therapy, Adverum announced it found the safety issues were more widespread: Five of 12 patients who received a high dose of the therapy saw “similar clinically-relevant events.”
Three required surgery on their treated eye. And all 12 are being recommended “aggressive immunomodulatory treatments” to prevent further injury.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.